Articles

The complex interplay between metabolic dysfunction and brain insulin resistance in schizophrenia warrants further investigation as it represents a unique opportunity for both mechanistic inquiry and the development of novel therapeutic strategies that can improve metabolic and cognitive outcomes in this population.

Virtual Reality (VR) technology enables a new form of exposure therapy through the creation of a so-called virtual world, known as “in-virtuo” exposure.

Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.

This article examines the limitations of current treatments for anxiety disorders and surveys promising new pharmacological approaches such as novel GABAergic agents, psychedelics, and neuropeptide modulators.

This article reviews the shift towards more personalised care by integrating biological and clinical profiles to guide mechanism-based, targeted interventions across psychiatric conditions.

This article discusses potential next steps for enhancing clinical trial outcomes in neurodegenerative diseases, with the ultimate goal of improving patient care